Immunoregulatory cells of the tumor microenvironment

Frontiers in Bioscience

Volumn 15, Issue 1, 2010, Pages 291-308

  Chatten, Christa ^a   Bathe, Oliver F ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Anergy; Cytotoxic T cells; Regulatory T cells; Review; Suppression; Tolerance; Tumor associated macrophages; Tumor microenvironment

Indexed keywords

AUTACOID;

ANIMAL; BIOLOGICAL MODEL; CELLULAR IMMUNITY; CYTOTOXICITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM; PATHOLOGY; REVIEW;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INFLAMMATION MEDIATORS; MODELS, IMMUNOLOGICAL; NEOPLASMS;

EID: 77951215835     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3621     Document Type: Article

References (191)

1. L. Gattinoni, D. J. Powell, Jr., S. A. Rosenberg and N. P. Restifo: Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6, 383-393 (2006).
2. F. K. Stevenson: Update on cancer vaccines. Curr Opin Oncol 17, 573-577 (2005). (Pubitemid 41566410)
3. P. D. Gregor, J. D. Wolchok, C. R. Ferrone, H. Buchinshky, J. A. Guevara-Patino, M. A. Perales, F. Mortazavi, D. Bacich, W. Heston, J. B. Latouche, M. Sadelain, J. P. Allison, H. I. Scher and A. N. Houghton: CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 22, 1700-1708 (2004). (Pubitemid 38447218)
4. A. A. Hurwitz, B. A. Foster, E. D. Kwon, T. Truong, E. M. Choi, N. M. Greenberg, M. B. Burg and J. P. Allison: Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60, 2444-2448 (2000). (Pubitemid 30262435)
5. P. Shrikant, A. Khoruts and M. F. Mescher: CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 11, 483-493 (1999). (Pubitemid 29504203)
6. A. van Elsas, A. A. Hurwitz and J. P. Allison: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)- producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190, 355-366 (1999). (Pubitemid 29374833)
7. M. E. Smith, S. G. Marsh, J. G. Bodmer, K. Gelsthorpe and W. F. Bodmer: Loss of HLA-A, B, C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia. Proc Natl Acad Sci U S A 86, 5557-5561 (1989). (Pubitemid 19185583)
8. M. E. Dudley and D. C. Roopenian: Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J Exp Med 184, 441-447 (1996). (Pubitemid 26324097)
9. O. F. Bathe, N. Dalyot-Herman and T. R. Malek: Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment. BMC Cancer 3, 21 (2003).
10. P. P. Lee, C. Yee, P. A. Savage, L. Fong, D. Brockstedt, J. S. Weber, D. Johnson, S. Swetter, J. Thompson, P. D. Greenberg, M. Roederer and M. M. Davis: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5, 677-685 (1999). (Pubitemid 29289432)
11. M. Hahne, D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini and J. Tschopp: Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363- 1366 (1996). (Pubitemid 26391458)
12. K. A. Zwicker, C. Chatten, K. Gratton, D. Demetrick, P. Serra, P. Santamaria and O. F. Bathe: Spontaneous autoimmunity sufficiently potent to induce diabetes mellitus is insufficient to protect against insulinoma. J Immunol, In Press (2009).
13. J. M. den Haan, G. Kraal and M. J. Bevan: Cutting edge: Lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response. J Immunol 178, 5429-5433 (2007). (Pubitemid 46674336)
14. S. Gregori, R. Bacchetta, L. Passerini, M. K. Levings and M. G. Roncarolo: Isolation, expansion, and characterization of human natural and adaptive regulatory T cells. Methods Mol Biol 380, 83-105 (2007). (Pubitemid 350183324)
15. S. G. Zheng, J. D. Gray, K. Ohtsuka, S. Yamagiwa and D. A. Horwitz: Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors. J Immunol 169, 4183-4189 (2002). (Pubitemid 35178188)
16. E. M. Shevach: From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25, 195-201 (2006). (Pubitemid 44224153)
17. D. J. Campbell and S. F. Ziegler: FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat Rev Immunol 7, 305-310 (2007). (Pubitemid 46480960)
18. C. C. Chang, R. Ciubotariu, J. S. Manavalan, J. Yuan, A. I. Colovai, F. Piazza, S. Lederman, M. Colonna, R. Cortesini, R. Dalla-Favera and N. Suciu-Foca: Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 3, 237-243 (2002). (Pubitemid 34218114)
19. J. D. Fontenot, M. A. Gavin and A. Y. Rudensky: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4, 330-336 (2003). (Pubitemid 36432314)
20. L. S. Taams, M. Vukmanovic-Stejic, J. Smith, P. J. Dunne, J. M. Fletcher, F. J. Plunkett, S. B. Ebeling, G. Lombardi, M. H. Rustin, J. W. Bijlsma, F. P. Lafeber, M. Salmon and A. N. Akbar: Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells. Eur J Immunol 32, 1621-1630 (2002). (Pubitemid 34679150)
21. M. Itoh, T. Takahashi, N. Sakaguchi, Y. Kuniyasu, J. Shimizu, F. Otsuka and S. Sakaguchi: Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162, 5317-5326 (1999). (Pubitemid 29307138)
22. Y. Kuniyasu, T. Takahashi, M. Itoh, J. Shimizu, G. Toda and S. Sakaguchi: Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int Immunol 12, 1145-1155 (2000). (Pubitemid 30618021)
23. W. Liu, A. L. Putnam, Z. Xu-Yu, G. L. Szot, M. R. Lee, S. Zhu, P. A. Gottlieb, P. Kapranov, T. R. Gingeras, G. B. Fazekas de St, C. Clayberger, D. M. Soper, S. F. Ziegler and J. A. Bluestone: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203, 1701-1711 (2006). (Pubitemid 44036276)
24. N. Seddiki, B. Santner-Nanan, J. Martinson, J. Zaunders, S. Sasson, A. Landay, M. Solomon, W. Selby, S. I. Alexander, R. Nanan, A. Kelleher and G. B. Fazekas de St: Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203, 1693-1700 (2006). (Pubitemid 44036275)
25. J. D. Kim, B. K. Choi, J. S. Bae, U. H. Lee, I. S. Han, H. W. Lee, B. S. Youn, D. S. Vinay and B. S. Kwon: Cloning and characterization of GITR ligand. Genes Immun 4, 564-569 (2003). (Pubitemid 38961152)
26. R. S. McHugh, M. J. Whitters, C. A. Piccirillo, D. A. Young, E. M. Shevach, M. Collins and M. C. Byrne: CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid- induced TNF receptor. Immunity 16, 311- 323 (2002). (Pubitemid 34211969)
27. K. Uraushihara, T. Kanai, K. Ko, T. Totsuka, S. Makita, R. Iiyama, T. Nakamura and M. Watanabe: Regulation of murine inflammatory bowel disease by CD25+ and. J Immunol 171, 708-716 (2003).
28. S. Read, V. Malmstrom and F. Powrie: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192, 295-302 (2000). (Pubitemid 30470312)
29. T. Takahashi, T. Tagami, S. Yamazaki, T. Uede, J. Shimizu, N. Sakaguchi, T. W. Mak and S. Sakaguchi: Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192, 303-310 (2000).
30. M. A. Gavin, S. R. Clarke, E. Negrou, A. Gallegos and A. Rudensky: Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol 3, 33-41 (2002). (Pubitemid 34065615)
31. L. S. Walker, A. Chodos, M. Eggena, H. Dooms and A. K. Abbas: Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med 198, 249-258 (2003). (Pubitemid 36992178)
32. S. Fisson, G. Darrasse-Jeze, E. Litvinova, F. Septier, D. Klatzmann, R. Liblau and B. L. Salomon: Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med 198, 737-746 (2003). (Pubitemid 37087773)
33. R. Setoguchi, S. Hori, T. Takahashi and S. Sakaguchi: Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201, 723-735 (2005). (Pubitemid 40395118)
34. H. Jonuleit, E. Schmitt, G. Schuler, J. Knop and A. H. Enk: Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192, 1213- 1222 (2000).
35. M. J. Benson, K. Pino-Lagos, M. Rosemblatt and R. J. Noelle: All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 204, 1765-1774 (2007). (Pubitemid 47236315)
36. M. Murakami, A. Sakamoto, J. Bender, J. Kappler and P. Marrack: CD25+CD4+ T cells contribute to the control of memory CD8+ T cells. Proc Natl Acad Sci U S A 99, 8832-8837 (2002). (Pubitemid 34693644)
37. C. A. Piccirillo and E. M. Shevach: Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167, 1137-1140 (2001). (Pubitemid 32703105)
38. A. M. Thornton and E. M. Shevach: CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188, 287-296 (1998). (Pubitemid 28357757)
39. J. Shimizu, S. Yamazaki and S. Sakaguchi: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163, 5211-5218 (1999).
40. M. K. Levings, R. Sangregorio, C. Sartirana, A. L. Moschin, M. Battaglia, P. C. Orban and M. G. Roncarolo: Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 196, 1335-1346 (2002). (Pubitemid 35375552)
41. P. Yu, Y. Lee, W. Liu, T. Krausz, A. Chong, H. Schreiber and Y. X. Fu: Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201, 779-791 (2005). (Pubitemid 40395122)
42. A. H. Tien, L. Xu and C. D. Helgason: Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer Res 65, 2947-2955 (2005). (Pubitemid 40490100)
43. T. Sasada, M. Kimura, Y. Yoshida, M. Kanai and A. Takabayashi: CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98, 1089- 1099 (2003). (Pubitemid 37022112)
44. F. Ichihara, K. Kono, A. Takahashi, H. Kawaida, H. Sugai and H. Fujii: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9, 4404- 4408 (2003). (Pubitemid 37248397)
45. U. K. Liyanage, T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure and D. C. Linehan: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169, 2756-2761 (2002). (Pubitemid 34921025)
46. O. Alhamarneh, S. M. Amarnath, N. D. Stafford and J. Greenman: Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer? Head Neck 30, 251-261 (2008). (Pubitemid 351251710)
47. E. Y. Woo, C. S. Chu, T. J. Goletz, K. Schlienger, H. Yeh, G. Coukos, S. C. Rubin, L. R. Kaiser and C. H. June: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61, 4766-4772 (2001). (Pubitemid 32691889)
48. E. Y. Woo, H. Yeh, C. S. Chu, K. Schlienger, R. G. Carroll, J. L. Riley, L. R. Kaiser and C. H. June: Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168, 4272-4276 (2002). (Pubitemid 34441324)
49. T. J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, Y. Zhu, S. Wei, I. Kryczek, B. Daniel, A. Gordon, L. Myers, A. Lackner, M. L. Disis, K. L. Knutson, L. Chen and W. Zou: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10, 942- 949 (2004). (Pubitemid 39273735)
50. A. M. Wolf, D. Wolf, M. Steurer, G. Gastl, E. Gunsilius and B. Grubeck-Loebenstein: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9, 606-612 (2003). (Pubitemid 36182591)
51. K. Kono, H. Kawaida, A. Takahashi, H. Sugai, K. Mimura, N. Miyagawa, H. Omata and H. Fujii: CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 55, 1064-1071 (2006). (Pubitemid 43800721)
52. D. Hawiger, K. Inaba, Y. Dorsett, M. Guo, K. Mahnke, M. Rivera, J. V. Ravetch, R. M. Steinman and M. C. Nussenzweig: Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194, 769-779 (2001). (Pubitemid 32983013)
53. K. Mahnke, Y. Qian, J. Knop and A. H. Enk: Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood 101, 4862-4869 (2003). (Pubitemid 36857748)
54. M. B. Lutz and G. Schuler: Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 23, 445-449 (2002). (Pubitemid 35015188)
55. M. C. Rissoan, V. Soumelis, N. Kadowaki, G. Grouard, F. Briere, M. R. de Waal and Y. J. Liu: Reciprocal control of T helper cell and dendritic cell differentiation. Science 283, 1183-1186 (1999).
56. F. Briere, N. Bendriss-Vermare, T. Delale, S. Burg, C. Corbet, M. C. Rissoan, L. Chaperot, J. Plumas, M. C. Jacob, G. Trinchieri and E. E. Bates: Origin and filiation of human plasmacytoid dendritic cells. Hum Immunol 63, 1081-1093 (2002). (Pubitemid 36025982)
57. M. Kuwana: Induction of anergic and regulatory T cells by plasmacytoid dendritic cells and other dendritic cell subsets. Hum Immunol 63, 1156-1163 (2002). (Pubitemid 36025990)
58. T. Ito, M. Inaba, K. Inaba, J. Toki, S. Sogo, T. Iguchi, Y. Adachi, K. Yamaguchi, R. Amakawa, J. Valladeau, S. Saeland, S. Fukuhara and S. Ikehara: A CD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells. J Immunol 163, 1409-1419 (1999). (Pubitemid 29352761)
59. L. Cederbom, H. Hall and F. Ivars: CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 30, 1538-1543 (2000). (Pubitemid 30342794)
60. N. Misra, J. Bayry, S. Lacroix-Desmazes, M. D. Kazatchkine and S. V. Kaveri: Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigenpresenting function of dendritic cells. J Immunol 172, 4676-4680 (2004). (Pubitemid 38456386)
61. H. W. Lim, P. Hillsamer, A. H. Banham and C. H. Kim: Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol 175, 4180-4183 (2005). (Pubitemid 41361949)
62. R. Houot, I. Perrot, E. Garcia, I. Durand and S. Lebecque: Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J Immunol 176, 5293-5298 (2006).
63. M. Veldhoen, H. Moncrieffe, R. J. Hocking, C. J. Atkins and B. Stockinger: Modulation of dendritic cell function by naive and regulatory CD4+ T cells. J Immunol 176, 6202-6210 (2006).
64. M. Thurnher, C. Radmayr, R. Ramoner, S. Ebner, G. Bock, H. Klocker, N. Romani and G. Bartsch: Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 68, 1-7 (1996). (Pubitemid 26354569)
65. D. Bell, P. Chomarat, D. Broyles, G. Netto, G. M. Harb, S. Lebecque, J. Valladeau, J. Davoust, K. A. Palucka and J. Banchereau: In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 190, 1417-1426 (1999).
66. T. J. Curiel, S. Wei, H. Dong, X. Alvarez, P. Cheng, P. Mottram, R. Krzysiek, K. L. Knutson, B. Daniel, M. C. Zimmermann, O. David, M. Burow, A. Gordon, N. Dhurandhar, L. Myers, R. Berggren, A. Hemminki, R. D. Alvarez, D. Emilie, D. T. Curiel, L. Chen and W. Zou: Blockade of B7-H1 improves myeloid dendritic cellmediated antitumor immunity. Nat Med 9, 562-567 (2003). (Pubitemid 36597102)
67. T. Schwaab, A. R. Schned, J. A. Heaney, B. F. Cole, J. Atzpodien, F. Wittke and M. S. Ernstoff: In vivo description of dendritic cells in human renal cell carcinoma. J Urol 162, 567-573 (1999). (Pubitemid 29434398)
68. A. Bergeron, F. El Hage, M. Kambouchner, D. Lecossier and A. Tazi: Characterisation of dendritic cell subsets in lung cancer micro-environments. Eur Respir J 28, 1170-1177 (2006). (Pubitemid 44883852)
69. N. A. Zeid and H. K. Muller: S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 25, 338- 343 (1993). (Pubitemid 24238309)
70. A. Ladanyi, J. Kiss, B. Somlai, K. Gilde, Z. Fejos, A. Mohos, I. Gaudi and J. Timar: Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 56, 1459-1469 (2007). (Pubitemid 47024707)
71. P. Chaux, M. Moutet, J. Faivre, F. Martin and M. Martin: Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest 74, 975-983 (1996). (Pubitemid 26152665)
72. M. Colonna, G. Trinchieri and Y. J. Liu: Plasmacytoid dendritic cells in immunity. Nat Immunol 5, 1219-1226 (2004). (Pubitemid 41057736)
73. W. Zou, V. Machelon, A. Coulomb-L'Hermin, J. Borvak, F. Nome, T. Isaeva, S. Wei, R. Krzysiek, I. Durand-Gasselin, A. Gordon, T. Pustilnik, D. T. Curiel, P. Galanaud, F. Capron, D. Emilie and T. J. Curiel: Stromalderived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7, 1339-1346 (2001). (Pubitemid 34007939)
74. E. Hartmann, B. Wollenberg, S. Rothenfusser, M. Wagner, D. Wellisch, B. Mack, T. Giese, O. Gires, S. Endres and G. Hartmann: Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63, 6478-6487 (2003). (Pubitemid 37255200)
75. W. Vermi, R. Bonecchi, F. Facchetti, D. Bianchi, S. Sozzani, S. Festa, A. Berenzi, M. Cella and M. Colonna: Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 200, 255-268 (2003). (Pubitemid 36748035)
76. D. I. Gabrilovich, J. Corak, I. F. Ciernik, D. Kavanaugh and D. P. Carbone: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3, 483-490 (1997). (Pubitemid 27158075)
77. J. B. Katz, A. J. Muller and G. C. Prendergast: Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 222, 206-221 (2008). (Pubitemid 351430372)
78. A. Takahashi, K. Kono, J. Itakura, H. Amemiya, T. R. Feng, H. Iizuka, H. Fujii and Y. Matsumoto: Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology 62, 121-127 (2002). (Pubitemid 34253081)
79. K. Ambe, M. Mori and M. Enjoji: S-100 proteinpositive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 63, 496-503 (1989). (Pubitemid 19038466)
80. A. Sica, T. Schioppa, A. Mantovani and P. Allavena: Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42, 717-727 (2006).
81. A. Mantovani, P. Allavena and A. Sica: Tumourassociated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer 40, 1660-1667 (2004). (Pubitemid 38902900)
82. A. B. Blom, T. R. Radstake, A. E. Holthuysen, A. W. Sloetjes, G. J. Pesman, F. G. Sweep, F. A. van de Loo, L. A. Joosten, P. Barrera, P. L. van Lent and W. B. van den Berg: Increased expression of Fcgamma receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor alpha and matrix metalloproteinase. Arthritis Rheum 48, 1002-1014 (2003). (Pubitemid 36418242)
83. A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi and M. Locati: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25, 677-686 (2004). (Pubitemid 39457982)
84. F. Balkwill and A. Mantovani: Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001). (Pubitemid 32173595)
85. S. Gordon: Alternative activation of macrophages. Nat Rev Immunol 3, 23-35 (2003). (Pubitemid 37328697)
86. C. F. Anderson and D. M. Mosser: A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol 72, 101-106 (2002).
87. S. Goerdt and C. E. Orfanos: Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 10, 137-142 (1999). (Pubitemid 29115619)
88. A. Mantovani, A. Sica and M. Locati: Macrophage polarization comes of age. Immunity 23, 344-346 (2005). (Pubitemid 41443435)
89. M. R. Young, M. A. Wright, Y. Lozano, M. M. Prechel, J. Benefield, J. P. Leonetti, S. L. Collins and G. J. Petruzzelli: Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer 74, 69-74 (1997). (Pubitemid 27157858)
90. F. O. Martinez, A. Sica, A. Mantovani and M. Locati: Macrophage activation and polarization. Front Biosci 13, 453-461 (2008). (Pubitemid 351599757)
91. M. Munder, K. Eichmann, J. M. Moran, F. Centeno, G. Soler and M. Modolell: Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol 163, 3771-3777 (1999). (Pubitemid 29450901)
92. V. Boutard, R. Havouis, B. Fouqueray, C. Philippe, J. P. Moulinoux and L. Baud: Transforming growth factorbeta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. J Immunol 155, 2077-2084 (1995).
93. A. C. Morrison and P. H. Correll: Activation of the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase by macrophage-stimulating protein results in the induction of arginase activity in murine peritoneal macrophages. J Immunol 168, 853-860 (2002). (Pubitemid 34049588)
94. M. M. Jost, E. Ninci, B. Meder, C. Kempf, N. Van Royen, J. Hua, B. Berger, I. Hoefer, M. Modolell and I. Buschmann: Divergent effects of GM-CSF and TGFbeta1 on bone marrow-derived macrophage arginase-1 activity, MCP-1 expression, and matrix metalloproteinase-12: a potential role during arteriogenesis. FASEB J 17, 2281- 2283 (2003). (Pubitemid 39561466)
95. P. C. Rodriguez, A. H. Zea, J. DeSalvo, K. S. Culotta, J. Zabaleta, D. G. Quiceno, J. B. Ochoa and A. C. Ochoa: L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol 171, 1232-1239 (2003). (Pubitemid 36900052)
96. P. C. Rodriguez, D. G. Quiceno, J. Zabaleta, B. Ortiz, A. H. Zea, M. B. Piazuelo, A. Delgado, P. Correa, J. Brayer, E. M. Sotomayor, S. Antonia, J. B. Ochoa and A. C. Ochoa: Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64, 5839-5849 (2004). (Pubitemid 39095585)
97. E. F. Redente, D. J. Orlicky, R. J. Bouchard and A. M. Malkinson: Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. Am J Pathol 170, 693-708 (2007). (Pubitemid 47339405)
98. D. Massi, C. Marconi, A. Franchi, F. Bianchini, M. Paglierani, S. Ketabchi, C. Miracco, M. Santucci and L. Calorini: Arginine metabolism in tumor-associated macrophages in cutaneous malignant melanoma: evidence from human and experimental tumors. Hum Pathol 38, 1516-1525 (2007). (Pubitemid 47418963)
99. G. H. Ghassabeh, P. De Baetselier, L. Brys, W. Noel, J. A. Van Ginderachter, S. Meerschaut, A. Beschin, F. Brombacher and G. Raes: Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions. Blood 108, 575-583 (2006). (Pubitemid 44061358)
100. S. K. Biswas, L. Gangi, S. Paul, T. Schioppa, A. Saccani, M. Sironi, B. Bottazzi, A. Doni, B. Vincenzo, F. Pasqualini, L. Vago, M. Nebuloni, A. Mantovani and A. Sica: A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NFkappaB and enhanced IRF-3/STAT1 activation). Blood 107, 2112-2122 (2006). (Pubitemid 43289397)
101. A. Sica, A. Saccani, B. Bottazzi, N. Polentarutti, A. Vecchi, J. van Damme and A. Mantovani: Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol 164, 762-767 (2000). (Pubitemid 30043699)
102. M. R. Dinapoli, C. L. Calderon and D. M. Lopez: The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J Exp Med 183, 1323- 1329 (1996).
103. A. H. Klimp, H. Hollema, C. Kempinga, A. G. van der Zee, E. G. de Vries and T. Daemen: Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res 61, 7305-7309 (2001). (Pubitemid 32946529)
104. A. Mantovani, S. Sozzani, M. Locati, P. Allavena and A. Sica: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23, 549-555 (2002). (Pubitemid 35223554)
105. S. Tsutsui, K. Yasuda, K. Suzuki, K. Tahara, H. Higashi and S. Era: Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 14, 425-431 (2005).
106. C. Y. Chai, W. T. Chen, W. C. Hung, W. Y. Kang, Y. C. Huang, Y. C. Su and C. H. Yang: Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. J Clin Pathol 61, 658-664 (2008).
107. R. D. Leek, C. E. Lewis, R. Whitehouse, M. Greenall, J. Clarke and A. L. Harris: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56, 4625-4629 (1996). (Pubitemid 26338061)
108. R. D. Leek, K. L. Talks, F. Pezzella, H. Turley, L. Campo, N. S. Brown, R. Bicknell, M. Taylor, K. C. Gatter and A. L. Harris: Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res 62, 1326-1329 (2002). (Pubitemid 34407787)
109. C. Murdoch, M. Muthana and C. E. Lewis: Hypoxia regulates macrophage functions in inflammation. J Immunol 175, 6257-6263 (2005). (Pubitemid 41598863)
110. R. Du, K. V. Lu, C. Petritsch, P. Liu, R. Ganss, E. Passegue, H. Song, S. Vandenberg, R. S. Johnson, Z. Werb and G. Bergers: HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13, 206-220 (2008). (Pubitemid 351318372)
111. C. Marconi, F. Bianchini, A. Mannini, G. Mugnai, S. Ruggieri and L. Calorini: Tumoral and macrophage uPAR and MMP-9 contribute to the invasiveness of B16 murine melanoma cells. Clin Exp Metastasis 25, 225-231 (2008).
112. K. Oguma, H. Oshima, M. Aoki, R. Uchio, K. Naka, S. Nakamura, A. Hirao, H. Saya, M. M. Taketo and M. Oshima: Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J (2008).
113. N. R. Miselis, Z. J. Wu, N. Van Rooijen and A. B. Kane: Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 7, 788-799 (2008). (Pubitemid 351551032)
114. A. Mantovani, T. Schioppa, C. Porta, P. Allavena and A. Sica: Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25, 315-322 (2006). (Pubitemid 44922352)
115. S. Ohno, H. Inagawa, D. K. Dhar, T. Fujii, S. Ueda, M. Tachibana, Y. Ohno, N. Suzuki, M. Inoue, G. Soma and N. Nagasue: Role of tumor-associated macrophages (TAM) in advanced gastric carcinoma: the impact on FasL-mediated counterattack. Anticancer Res 25, 463-470 (2005). (Pubitemid 40470051)
116. C. H. Lee, I. Espinosa, S. Vrijaldenhoven, S. Subramanian, K. D. Montgomery, S. Zhu, R. J. Marinelli, J. L. Peterse, N. Poulin, T. O. Nielsen, R. B. West, C. B. Gilks and R. M. van de: Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res 14, 1423-1430 (2008). (Pubitemid 351413925)
117. X. D. Zhu, J. B. Zhang, P. Y. Zhuang, H. G. Zhu, W. Zhang, Y. Q. Xiong, W. Z. Wu, L. Wang, Z. Y. Tang and H. C. Sun: High expression of macrophage colonystimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 26, 2707-2716 (2008).
118. B. D. Hansen, H. Schmidt, M. H. von der, P. Sjoegren, R. Agger and M. Hokland: Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy. Acta Oncol 45, 400-405 (2006). (Pubitemid 43884607)
119. I. Marigo, L. Dolcetti, P. Serafini, P. Zanovello and V. Bronte: Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222, 162-179 (2008). (Pubitemid 351430364)
120. G. Gallina, L. Dolcetti, P. Serafini, C. De Santo, I. Marigo, M. P. Colombo, G. Basso, F. Brombacher, I. Borrello, P. Zanovello, S. Bicciato and V. Bronte: Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 116, 2777-2790 (2006). (Pubitemid 44511641)
121. V. Bronte, E. Apolloni, A. Cabrelle, R. Ronca, P. Serafini, P. Zamboni, N. P. Restifo and P. Zanovello: Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 96, 3838-3846 (2000).
122. A. S. Pak, M. A. Wright, J. P. Matthews, S. L. Collins, G. J. Petruzzelli and M. R. Young: Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocytemacrophage colony-stimulating factor. Clin Cancer Res 1, 95-103 (1995).
123. M. R. Young, G. J. Petruzzelli, K. Kolesiak, N. Achille, D. M. Lathers and D. I. Gabrilovich: Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34(+) progenitor cells. Hum Immunol 62, 332-341 (2001). (Pubitemid 32298975)
124. B. Almand, J. I. Clark, E. Nikitina, J. van Beynen, N. R. English, S. C. Knight, D. P. Carbone and D. I. Gabrilovich: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166, 678-689 (2001). (Pubitemid 32038493)
125. A. H. Zea, P. C. Rodriguez, M. B. Atkins, C. Hernandez, S. Signoretti, J. Zabaleta, D. McDermott, D. Quiceno, A. Youmans, A. O'Neill, J. Mier and A. C. Ochoa: Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65, 3044-3048 (2005). (Pubitemid 40524582)
126. P. Filipazzi, R. Valenti, V. Huber, L. Pilla, P. Canese, M. Iero, C. Castelli, L. Mariani, G. Parmiani and L. Rivoltini: Identification of a new
127. S. Nagaraj, K. Gupta, V. Pisarev, L. Kinarsky, S. Sherman, L. Kang, D. L. Herber, J. Schneck and D. I. Gabrilovich: Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 13, 828-835 (2007). (Pubitemid 47038194)
128. S. Kusmartsev, Y. Nefedova, D. Yoder and D. I. Gabrilovich: Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172, 989-999 (2004). (Pubitemid 38113758)
129. V. Bronte, P. Serafini, C. De Santo, I. Marigo, V. Tosello, A. Mazzoni, D. M. Segal, C. Staib, M. Lowel, G. Sutter, M. P. Colombo and P. Zanovello: IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 170, 270-278 (2003). (Pubitemid 36026149)
130. P. Sinha, V. K. Clements and S. Ostrand-Rosenberg: Interleukin-13- regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 65, 11743-11751 (2005). (Pubitemid 41821736)
131. B. Huang, P. Y. Pan, Q. Li, A. I. Sato, D. E. Levy, J. Bromberg, C. M. Divino and S. H. Chen: Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and Tcell anergy in tumor-bearing host. Cancer Res 66, 1123- 1131 (2006). (Pubitemid 43165981)
132. P. Y. Pan, G. X. Wang, B. Yin, J. Ozao, T. Ku, C. M. Divino and S. H. Chen: Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111, 219-228 (2008).
133. C. Liu, S. Yu, J. Kappes, J. Wang, W. E. Grizzle, K. R. Zinn and H. G. Zhang: Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumorbearing host. Blood 109, 4336-4342 (2007). (Pubitemid 46743401)
134. E. Suzuki, V. Kapoor, A. S. Jassar, L. R. Kaiser and S. M. Albelda: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11, 6713-6721 (2005). (Pubitemid 41339014)
135. P. Sinha, V. K. Clements, S. K. Bunt, S. M. Albelda and S. Ostrand-Rosenberg: Cross-talk between myeloidderived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179, 977- 983 (2007).
136. N. Umemura, M. Saio, T. Suwa, Y. Kitoh, J. Bai, K. Nonaka, G. F. Ouyang, M. Okada, M. Balazs, R. Adany, T. Shibata and T. Takami: Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 83, 1136-1144 (2008). (Pubitemid 351960345)
137. J. Cui, T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno and M. Taniguchi: Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278, 1623-1626 (1997). (Pubitemid 27516281)
138. T. Kawano, J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, H. Koseki and M. Taniguchi: CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278, 1626-1629 (1997). (Pubitemid 27516282)
139. M. Terabe, S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D. D. Donaldson, D. P. Carbone, W. E. Paul and J. A. Berzofsky: NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1, 515-520 (2000).
140. M. Terabe, S. Matsui, J. M. Park, M. Mamura, N. Noben-Trauth, D. D. Donaldson, W. Chen, S. M. Wahl, S. Ledbetter, B. Pratt, J. J. Letterio, W. E. Paul and J. A. Berzofsky: Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocytemediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198, 1741-1752 (2003). (Pubitemid 37494166)
141. J. M. Park, M. Terabe, L. T. van den Broeke, D. D. Donaldson and J. A. Berzofsky: Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. Int J Cancer 114, 80-87 (2005). (Pubitemid 40194311)
142. M. Terabe, J. Swann, E. Ambrosino, P. Sinha, S. Takaku, Y. Hayakawa, D. I. Godfrey, S. Ostrand-Rosenberg, M. J. Smyth and J. A. Berzofsky: A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 202, 1627-1633 (2005). (Pubitemid 41815868)
143. S. Ostrand-Rosenberg, V. K. Clements, M. Terabe, J. M. Park, J. A. Berzofsky and S. K. Dissanayake: Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFNgamma dependent. J Immunol 169, 5796-5804 (2002). (Pubitemid 35291682)
144. M. Terabe, C. Khanna, S. Bose, F. Melchionda, A. Mendoza, C. L. Mackall, L. J. Helman and J. A. Berzofsky: CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta. Cancer Res 66, 3869- 3875 (2006).
145. E. Ambrosino, M. Terabe, R. C. Halder, J. Peng, S. Takaku, S. Miyake, T. Yamamura, V. Kumar and J. A. Berzofsky: Cross-regulation between type I and type II NKT cells in regulating tumor immunity: A new immunoregulatory axis. J Immunol 179, 5126-5136 (2007).
146. M. Terabe and J. A. Berzofsky: NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol 28, 491-496 (2007). (Pubitemid 350087811)
147. R. Liu, A. La Cava, X. F. Bai, Y. Jee, M. Price, D. I. Campagnolo, P. Christadoss, T. L. Vollmer, L. Van Kaer and F. D. Shi: Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol 175, 7898-7904 (2005). (Pubitemid 41798350)
148. A. Bartholomew, C. Sturgeon, M. Siatskas, K. Ferrer, K. McIntosh, S. Patil, W. Hardy, S. Devine, D. Ucker, R. Deans, A. Moseley and R. Hoffman: Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30, 42-48 (2002). (Pubitemid 34059216)
149. M. Di Nicola, C. Carlo-Stella, M. Magni, M. Milanesi, P. D. Longoni, P. Matteucci, S. Grisanti and A. M. Gianni: Human bone marrow stromal cells suppress Tlymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838-3843 (2002). (Pubitemid 34534559)
150. M. Krampera, S. Glennie, J. Dyson, D. Scott, R. Laylor, E. Simpson and F. Dazzi: Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101, 3722-3729 (2003). (Pubitemid 36857965)
151. S. Glennie, I. Soeiro, P. J. Dyson, E. W. Lam and F. Dazzi: Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105, 2821-2827 (2005). (Pubitemid 40446275)
152. J. Plumas, L. Chaperot, M. J. Richard, J. P. Molens, J. C. Bensa and M. C. Favrot: Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 19, 1597-1604 (2005). (Pubitemid 43090404)
153. S. Beyth, Z. Borovsky, D. Mevorach, M. Liebergall, Z. Gazit, H. Aslan, E. Galun and J. Rachmilewitz: Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105, 2214-2219 (2005). (Pubitemid 40731815)
154. A. J. Nauta, A. B. Kruisselbrink, E. Lurvink, R. Willemze and W. E. Fibbe: Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 177, 2080-2087 (2006). (Pubitemid 44200965)
155. R. Ramasamy, H. Fazekasova, E. W. Lam, I. Soeiro, G. Lombardi and F. Dazzi: Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 83, 71-76 (2007). (Pubitemid 46104974)
156. A. Corcione, F. Benvenuto, E. Ferretti, D. Giunti, V. Cappiello, F. Cazzanti, M. Risso, F. Gualandi, G. L. Mancardi, V. Pistoia and A. Uccelli: Human mesenchymal stem cells modulate B-cell functions. Blood 107, 367-372 (2006). (Pubitemid 43053565)
157. G. M. Spaggiari, A. Capobianco, S. Becchetti, M. C. Mingari and L. Moretta: Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2- induced NK-cell proliferation. Blood 107, 1484-1490 (2006). (Pubitemid 43242385)
158. S. Jones, N. Horwood, A. Cope and F. Dazzi: The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol 179, 2824-2831 (2007).
159. M. A. Haniffa, X. N. Wang, U. Holtick, M. Rae, J. D. Isaacs, A. M. Dickinson, C. M. Hilkens and M. P. Collin: Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol 179, 1595-1604 (2007).
160. S. Lob and A. Konigsrainer: Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction? Langenbecks Arch Surg (2007).
161. C. Schaefer, G. G. Kim, A. Albers, K. Hoermann, E. N. Myers and T. L. Whiteside: Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92, 913-920 (2005). (Pubitemid 40462639)
162. S. Yamagiwa, J. D. Gray, S. Hashimoto and D. A. Horwitz: A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 166, 7282-7289 (2001). (Pubitemid 32525603)
163. D. R. Smith, S. L. Kunkel, M. D. Burdick, C. A. Wilke, M. B. Orringer, R. I. Whyte and R. M. Strieter: Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 145, 18-25 (1994). (Pubitemid 24217477)
164. S. Kruger-Krasagakes, K. Krasagakis, C. Garbe, E. Schmitt, C. Huls, T. Blankenstein and T. Diamantstein: Expression of interleukin 10 in human melanoma. Br J Cancer 70, 1182-1185 (1994). (Pubitemid 24358959)
165. S. G. Zheng, J. H. Wang, J. D. Gray, H. Soucier and D. A. Horwitz: Natural and induced CD4+CD25+ cells educate CD4+. J Immunol 172, 5213-5221 (2004).
166. H. Y. Wang, D. A. Lee, G. Peng, Z. Guo, Y. Li, Y. Kiniwa, E. M. Shevach and R. F. Wang: Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20, 107-118 (2004). (Pubitemid 38134298)
167. D. I. Gabrilovich, H. L. Chen, K. R. Girgis, H. T. Cunningham, G. M. Meny, S. Nadaf, D. Kavanaugh and D. P. Carbone: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2, 1096-1103 (1996). (Pubitemid 26338628)
168. D. Gabrilovich, T. Ishida, T. Oyama, S. Ran, V. Kravtsov, S. Nadaf and D. P. Carbone: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150- 4166 (1998). (Pubitemid 28544331)
169. M. R. Shurin, G. V. Shurin, A. Lokshin, Z. R. Yurkovetsky, D. W. Gutkin, G. Chatta, H. Zhong, B. Han and R. L. Ferris: Intratumoral cytokines/chemokines/ growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 25, 333-356 (2006). (Pubitemid 44922354)
170. M. Ratta, F. Fagnoni, A. Curti, R. Vescovini, P. Sansoni, B. Oliviero, M. Fogli, E. Ferri, G. R. Della Cuna, S. Tura, M. Baccarani and R. M. Lemoli: Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100, 230-237 (2002). (Pubitemid 35177452)
171. K. Steinbrink, M. Wolfl, H. Jonuleit, J. Knop and A. H. Enk: Induction of tolerance by IL-10-treated dendritic cells. J Immunol 159, 4772-4780 (1997). (Pubitemid 127471012)
172. T. Ueno, M. Toi, H. Saji, M. Muta, H. Bando, K. Kuroi, M. Koike, H. Inadera and K. Matsushima: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6, 3282-3289 (2000). (Pubitemid 30637758)
173. E. Azenshtein, G. Luboshits, S. Shina, E. Neumark, D. Shahbazian, M. Weil, N. Wigler, I. Keydar and A. Ben Baruch: The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 62, 1093-1102 (2002). (Pubitemid 34160293)
174. H. Saji, M. Koike, T. Yamori, S. Saji, M. Seiki, K. Matsushima and M. Toi: Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92, 1085-1091 (2001). (Pubitemid 32861655)
175. M. C. Duyndam, M. C. Hilhorst, H. M. Schluper, H. M. Verheul, P. J. van Diest, G. Kraal, H. M. Pinedo and E. Boven: Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol 160, 537-548 (2002). (Pubitemid 34160331)
176. S. P. Dineen, K. D. Lynn, S. E. Holloway, A. F. Miller, J. P. Sullivan, D. S. Shames, A. W. Beck, C. C. Barnett, J. B. Fleming and R. A. Brekken: Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 68, 4340-4346 (2008).
177. P. Sinha, V. K. Clements and S. Ostrand-Rosenberg: Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174, 636-645 (2005). (Pubitemid 40094255)
178. S. Salvadori, G. Martinelli and K. Zier: Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 164, 2214-2220 (2000). (Pubitemid 30108782)
179. C. Melani, C. Chiodoni, G. Forni and M. P. Colombo: Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102, 2138-2145 (2003). (Pubitemid 37122391)
180. M. M. Mueller, W. Peter, M. Mappes, A. Huelsen, H. Steinbauer, P. Boukamp, M. Vaccariello, J. Garlick and N. E. Fusenig: Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colonystimulating factor and granulocyte-macrophage colonystimulating factor. Am J Pathol 159, 1567-1579 (2001). (Pubitemid 32947984)
181. N. Rochet, J. Dubousset, C. Mazeau, E. Zanghellini, M. F. Farges, H. S. de Novion, A. Chompret, B. Delpech, N. Cattan, M. Frenay and J. Gioanni: Establishment, characterisation and partial cytokine expression profile of a new human osteosarcoma cell line (CAL 72). Int J Cancer 82, 282-285 (1999). (Pubitemid 29293789)
182. M. Wislez, J. Fleury-Feith, N. Rabbe, J. Moreau, D. Cesari, B. Milleron, C. Mayaud, M. Antoine, P. Soler and J. Cadranel: Tumor-derived granulocyte-macrophage colony-stimulating factor and granulocyte colonystimulating factor prolong the survival of neutrophils infiltrating bronchoalveolar subtype pulmonary adenocarcinoma. Am J Pathol 159, 1423-1433 (2001). (Pubitemid 32947972)
183. A. Sica and V. Bronte: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117, 1155-1166 (2007). (Pubitemid 46718400)
184. S. K. Biswas, A. Sica and C. E. Lewis: Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 180, 2011- 2017 (2008).
185. A. Saccani, T. Schioppa, C. Porta, S. K. Biswas, M. Nebuloni, L. Vago, B. Bottazzi, M. P. Colombo, A. Mantovani and A. Sica: p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 66, 11432-11440 (2006). (Pubitemid 46009975)
186. C. Uyttenhove, L. Pilotte, I. Theate, V. Stroobant, D. Colau, N. Parmentier, T. Boon and B. J. Van den Eynde: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med 9, 1269-1274 (2003). (Pubitemid 37279849)
187. K. Ino, E. Yamamoto, K. Shibata, H. Kajiyama, N. Yoshida, M. Terauchi, A. Nawa, T. Nagasaka, O. Takikawa and F. Kikkawa: Inverse correlation between tumoral indoleamine 2, 3-dioxygenase expression and tumorinfiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 14, 2310-2317 (2008). (Pubitemid 351551062)
188. A. L. Mellor and D. H. Munn: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4, 762-774 (2004). (Pubitemid 39336293)
189. D. H. Munn, M. D. Sharma, D. Hou, B. Baban, J. R. Lee, S. J. Antonia, J. L. Messina, P. Chandler, P. A. Koni and A. L. Mellor: Expression of indoleamine 2, 3- dioxygenase by plasmacytoid dendritic cells in tumordraining lymph nodes. J Clin Invest 114, 280-290 (2004). (Pubitemid 39071633)
190. C. M. Della, S. Carlomagno, G. Frumento, M. Balsamo, C. Cantoni, R. Conte, L. Moretta, A. Moretta and M. Vitale: The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 108, 4118- 4125 (2006). (Pubitemid 44913283)
191. N. C. Direkze, K. Hodivala-Dilke, R. Jeffery, T. Hunt, R. Poulsom, D. Oukrif, M. R. Alison and N. A. Wright: Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 64, 8492-8495 (2004). (Pubitemid 39552057)